Cd4 cre b6 cg tg cd4 cre 1cwi bfluj

Manufactured by Jackson ImmunoResearch

Sourced in Montenegro

CD4-Cre (B6.Cg-Tg(Cd4-cre)1Cwi/BfluJ) is a transgenic mouse strain that expresses the Cre recombinase enzyme under the control of the Cd4 gene promoter. The Cre recombinase is a site-specific DNA recombinase that catalyzes the deletion of DNA sequences flanked by loxP sites. This product is intended for use in genetic studies involving T cell-specific gene manipulation.

Automatically generated - may contain errors

Lab products found in correlation

5 protocols using cd4 cre b6 cg tg cd4 cre 1cwi bfluj

Genetically Engineered Mouse Models for Immunological Research

Check if the same lab product or an alternative is used in the 5 most similar protocols

C57BL/6J, CD4^cre (B6.Cg-Tg(Cd4-cre)1Cwi/BfluJ), Mb1^cre (B6.C(Cg)-Cd79a^tm1(cre)Reth/EhobJ), MRL/lpr (MRL/MpJ-Fas^lpr/J), SLE¹²³ (B6;NZM-Sle1^NZM2410/Aeg Sle2^NZM2410/Aeg Sle3^NZM2410/Aeg/LmoJ), and Rosa26^eYFP (B6.Cg-Gt(ROSA)26Sor^{tm3(CAG-EYFP)Hze}/J) mice were obtained from The Jackson Laboratory (Bar Harbor, ME). T-bet-cre^ERT2 mice were generated by Dr. Lin Gan at the University of Rochester, Rochester, NY. Adora2a^flox (B6;129-Adora2a^tm1Dyj/J) mice were provided by Dr. Joel Linden, La Jolla Institute for Immunology, La Jolla, CA. All mice, except for the MRL/MpJ-Fas^lpr/J, were on the C57BL/6J background. All mice were housed and bred in the SUNY Upstate Medical University Animal Care Facility (Syracuse, NY), in accordance with institutional guidelines for animal welfare. All mice used for experiments were at least 6 weeks old, and both male and female mice were used unless otherwise stated. All studies involving animals were approved by the SUNY Upstate Medical University Institutional Animal Care and Use Committee NYSDOH Unit A073 IACUC number 311.

Levack R.C., Newell K.L., Cabrera-Martinez B., Cox J., Perl A., Bastacky S.I, & Winslow G.M. (2022). Adenosine receptor 2a agonists target mouse CD11c+T-bet+ B cells in infection and autoimmunity. Nature Communications, 13, 452.

+ Open protocol

+ Expand

Genetically Modified Murine Model of Lupus

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were housed in the pathogen-free facility in Yale Animal Resources Center (Yale University, New Haven, CT). Animal handling and experimental protocols were approved by the Yale Institutional Animal Care & Use Committee (IACUC). C57BL/6 (B6) mice were purchased from Charles River Laboratory. MRL/MpJ-Fas^lpr/J (MRL/lpr), CD4-Cre(B6.Cg-Tg[Cd4-cre]1Cwi/BfluJ), and Hif1a^fl/fl (B6.129-Hif1atm3Rsjo/J) mice were purchased from the Jackson Laboratory. B6.Sle1.Yaa mice were provided by E. Wakeland (University of Texas Southwestern Medical School). To generate Cd4cre.Hif1a^fl/fl.B6.Sle1.Yaa, Cd4cre mice and Hif1a^fl/fl mice were crossed to the B6.Sle1.Yaa background. Presence of the intact Sle1 locus was confirmed by microsatellite screening within the locus, including D1Mit15, D1Mit17, D1Mit47, D1Mit202, D1Mit113, D1Mit206, D1Mit353, D1Mit407, D1Mit105, D1Mit274, D1Mit400, and D1Mit541 (57 (link)).

Chen P.M., Wilson P.C., Shyer J.A., Veselits M., Steach H.R., Cui C., Moeckel G., Clark M.R, & Craft J. (2020). Kidney Tissue Hypoxia Dictates T-Cell Mediated Injury in Murine Lupus Nephritis. Science translational medicine, 12(538), eaay1620.

+ Open protocol

+ Expand

Conditional Knockout of Bhlhe40 in Mice

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

All mice used were on a C57BL/6 background. WT C57BL/6J, CD4-Cre (B6.Cg-Tg(Cd4-cre)1Cwi/BfluJ), LysM-Cre (B6N.129P2(B6)-Lyz2tm1(cre)Ifo/J), Bhlhe40 knockout (KO) (B6.129S1(Cg)-Bhlhe40tm1.1Rhli/MpmJ), OT-I T-cell receptor (TCR) transgenic (Tg(TcraTcrb)1100Mjb/J), and OT-II TCR transgenic (B6.Cg-Tg(TcraTcrb)425Cbn/J) mice were purchased from Jackson Labs. All in vivo experiments used 8–12-week-old female or male mice (to match the sex and strain of the tumors). All mice were housed in a specific pathogen-free animal facility. Bhlhe40^−/− (ten generations backcrossed to the C57BL/6 background) and Bhlhe40^f/f mice have been previously reported (11 (link),16 (link),24 (link)). For experiments using conditional Bhlhe40 KO mice, Bhlhe40^f/f littermates were used as controls. All animal studies were performed in accordance with, and with the approval of the Institutional Animal Care and Use Committee (IACUC) of Washington University and The University of Texas MD Anderson Cancer Center.

Salmon A.J., Shavkunov A.S., Miao Q., Jarjour N.N., Keshari S., Esaulova E., Williams C.D., Ward J.P., Highsmith A.M., Pineda J.E., Taneja R., Chen K., Edelson B.T, & Gubin M.M. (2022). BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy. Cancer Immunology Research, 10(5), 597-611.

+ Open protocol

+ Expand

Genetic Mouse Models for Tumor Immunology

Check if the same lab product or an alternative is used in the 5 most similar protocols

C57BL/6 (B6) mice were obtained from Envigo (Indianapolis, IN). R26Stop^FLikk2ca mice (C57BL/6-Gt(ROSA)26Sor^{tm1(Ikbkb)Rsky}/J) and CD4Cre (B6.Cg-Tg(Cd4-cre)1Cwi/BfluJ) were obtained from Jackson Laboratories. LckCreER mice were generated by cloning the cDNA encoding a tamoxifen-inducible Cre recombinase, into a cassette containing the Lck proximal promoter and a human CD2 enhancer (18 ). The tamoxifen-inducible Cre recombinase was generated by fusing Cre with a mutated form of the estrogen receptor (Cre-ERT2 fusion protein, from Addgene plasmid 14797) (19 ), such that tamoxifen administration (but not endogenous estrogen) results in Cre recombinase activity. 2C/RAG-KO (Thy1.1⁺/Thy1.2⁺) and OTI/RAG-KO (Thy1.1⁺) transgenic mice were maintained in the laboratory following crossing of 2C and OTI transgenic mice to RAG2-KO mice (Jackson Laboratories).
The B16.F10 spontaneous melanoma cell line was purchased from American Type Culture Collection. B16.SIY was engineered to express the model antigen SIYRYYGL, which can be recognized by CD8⁺ T cells in the context of H2-K^b (20 (link)).

Evaristo C., Spranger S., Barnes S.E., Miller M.L., Molinero L.L., Locke F., Gajewski T.F, & Alegre M.L. (2016). Engineering Active IKKβ in T Cells Drives Tumor Rejection. Journal of immunology (Baltimore, Md. : 1950), 196(7), 2933-2938.

+ Open protocol

+ Expand

Conditional Bhlhe40 Knockout Mice

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

All mice used were on a C57BL/6 background. WT C57BL/6J, CD4-Cre (B6.Cg-Tg(Cd4-cre)1Cwi/BfluJ), LysM-Cre (B6N.129P2(B6)-Lyz2tm1(cre)Ifo/J), Bhlhe40 knockout (KO) (B6.129S1(Cg)-Bhlhe40tm1.1Rhli/MpmJ), OT-I T-cell receptor (TCR) transgenic (Tg(TcraTcrb)1100Mjb/J) and OT-II TCR transgenic (B6.Cg-Tg(TcraTcrb)425Cbn/J) mice were purchased from Jackson Labs. All in vivo experiments used 8- to 12-week-old female or male mice (to match the sex and strain of the tumors). All mice were housed in a specific pathogen-free animal facility. Bhlhe40^–/– (ten generations backcrossed to the C57BL/6 background) and Bhlhe40^f/f mice have been previously reported (11, 16, 24 (link)). For experiments using conditional Bhlhe40 KO mice, Bhlhe40^f/f littermates were used as controls. All animal studies were performed in accordance with, and with the approval of the Institutional Animal Care and Use Committee (IACUC) of Washington University (St. Louis) and The University of Texas MD Anderson Cancer Center (Houston, TX).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!